CISPLATIN ETOPOSIDE CHEMOTHERAPY FOR RECURRENT OR PRIMARILY ADVANCED CERVICAL-CARCINOMA/

Thirty-eight women with primarily advanced (n = 10) or recurrent (n = 25) cervical carcinoma were treated with cisplatin (30 mg/m(2)/day int ravenously) and etoposide (60 mg/m(2)/day intravenously) for 3 days fo llowed by oral etoposide, 50 mg daily for 7 days, repeated at 28-day i ntervals, The response rate was 39% (95% confidence limits 24-55%) wit h response duration of 5 to 36 months. The main toxicities were neutro penia (21% developing neutropenic fever), alopecia, stomatitis, and na usea and vomiting, Despite this all responders had maintained or impro ved quality of life as defined by symptoms and performance, status. (C ) 1997 Academic Press.